Determinación del polimorfismo de CYP2C9*2 y su relación con la farmacocinética de acenocumarol en voluntarios sanos

background: most of the patients receiving anticoagulant therapy for extended periods show variability in their clinical response. acenocumarol, the most commonly prescribed oral anticoagulant in our country, is biotransformed mainly through cyp2c9 and recent research shows that cyp2c9*2 variant is partly responsible for the variable response to ace-nocumarol. aim: to determine pharmacokinetics parameters of acenocumarol in volunteers exhibiting the cyp2c9*2 polymorphic variant. methods: genotype detection was performed using pcr-rflp and pharmacokinetics parameters were obtained from the acenocumarol concentrations, using a uplc-ms/ms validated method. the project was approved by the institutional ethics committee of the university of chile's faculty of medicine. results: 19 out of 24 volunteers had the cyp2c9*1/*1 genotype, 4 the cyp2c9*1/*2 genotype (heterozygous) and 1 subject had the cyp2c9*2/*2 genotype (recessive homozygous). no statistically significant differences between acenocumarol pharmacokinetics parameters of cyp2c9*2 compared to those with normal variant, cyp2c9*1were observed.. however, a single individual with the cyp2c9*2/*2 genotype showed different phar-macokinetics parameters: tmáx and t1/2 were increased 1.4 and 1.7 times, respectively, and kc was 1.8 times lower compared to the group with the cyp2c9*1/*1 genotype. conclusion: there are clear differences in genotype-dependent acenocoumarol pharmacokinetics in individuals with the cyp2c9*2/*2 genotype, reflecting a potential relevance of this polymorphism in anticoagulation with acenocumarol.